肿瘤学多维预后指数是有前景的决策工具:一项针对老年转移性结直肠癌患者的真实世界分析
该真实世界分析纳入2010至2020年连续488例年龄≥70岁的转移性结直肠癌患者,中位年龄76.1岁。根据综合老年评估(CGA),52%为适合、28%为脆弱、20%为衰弱;根据肿瘤学多维预后指数(onco-MPI),9%为低危、54%为中危、37%为高危。中位总生存期为22.7个月,ECOG PS 0-1、低onco-MPI、CGA适合、接受化疗和双药方案改善总生存;化疗与onco-MPI评分显著相关,并在各风险亚组中带来生存获益。
要点
- CGA和onco-MPI评分在老年mCRC患者中证实具有预后价值。
- ECOG PS 0-1、低onco-MPI、CGA适合、化疗和双药方案与总生存改善相关。
- 化疗与onco-MPI评分显著相关,在各风险亚组中均带来生存获益。
核心结论
- CGA和onco-MPI评分在老年mCRC患者中证实具有预后影响,可能有助于决策和专用试验中的亚组分层。
研究设计与样本
- 真实世界分析,数据来自2010至2020年前瞻性维护的数据库,纳入连续488例年龄≥70岁的转移性结直肠癌患者。
- 计算基于CGA域的经验证算法得出的onco-MPI,使用Pearson检验验证onco-MPI评分与化疗给药是否相关。
主要发现
- 患者平均年龄76.1岁;根据CGA,52%为适合、28%为脆弱、20%为衰弱;根据onco-MPI,9%为低危、54%为中危、37%为高危。
- 中位总生存期为22.7个月。
- 以下因素改善总生存:ECOG PS 0-1、低onco-MPI、CGA适合、接受化疗和双药方案。
- 化疗给药与onco-MPI评分显著相关,在各风险亚组中均带来生存获益。
- 一线方案在CGA和onco-MPI各类别中对生存无影响。
临床怎么用
- CGA和onco-MPI评分可能有助于老年mCRC患者的决策和专用试验中的亚组分层(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 50% of colorectal cancers occur in older patients. International societies recommend geriatric tools to optimise treatment of older patients. Comprehensive Geriatric Assessment (CGA) is a multidimensional assessment used to classify patients as fit, vulnerable, or frail. The CGA-based oncological multidimensional prognostic index (onco-MPI) also classifies patients as high-, intermediate-, or low-risk based on tumour characteristics. We investigated the role of CGA and onco-MPI in older patients with metastatic colorectal cancer (mCRC) in a real-world setting. METHODS: Data for consecutive mCRC patients aged ≥70 years were retrieved from a prospectively maintained database from 2010 to 2020. We analyzed patients' and tumours' characteristics, and the CGA domains. Onco-MPI was calculated by a validated algorithm derived from CGA domains. Pearson's test was used to verify whether onco-MPI scores and chemotherapy administration were correlated. RESULTS: The study included 488 mCRC patients with a mean age of 76.1 years. According to CGA, 52% of patients were fit, 28% vulnerable, and 20% frail. According to onco-MPI, 9% were low, 54% intermediate, and 37% high-risk. The median OS was 22.7 months. The following factors improved OS: 0-1 ECOG PS, low onco-MPI, fit based on CGA, chemotherapy administration, and doublet regimen. Chemotherapy administration significantly correlated with onco-MPI scores, leading to a survival gain regardless of the risk subgroups. First-line regimen had no impact on survival across the CGA and onco-MPI categories. CONCLUSION: CGA and onco-MPI scores confirmed their prognostic impact in older mCRC patients and may aid in decision-making and subgroup stratification in dedicated trials.
引用
- Procaccio L, Bergamo F, Gatti M, et al. The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer. Eur J Cancer. 2022. PMID: 36335781. doi:10.1016/j.ejca.2022.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。